Entrada Therapeutics presents Phase 1/2 DMD trial data for ENTR-601-44.

Entrada shared a corporate presentation on its ENTR-601-44 candidate in Duchenne muscular dystrophy, outlining expectations for open-label period completion by end-2026 and multiple dose cohorts with escalating exposure. The presentation contains forward-looking statements about dystrophin restoration, functional improvements, and potential regulatory pathways including U.S. Accelerated Approval.